Information:
Error:
ID
12959
Description
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression; ODM derived from: https://clinicaltrials.gov/show/NCT00033514
Link
https://clinicaltrials.gov/show/NCT00033514
Keywords
Versions (1)
- 1/7/16 1/7/16 -
Uploaded on
January 7, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Breast Cancer NCT00033514
Eligibility Breast Cancer NCT00033514
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00033514
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
age, gender
Item
women aged > 18 years
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0079399 (UMLS CUI [2])
histology metastasis
Item
histologically documents metastatic breast cancer
boolean
C0019638 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
FISH her2 positive
Item
her2 positive using fish
boolean
C0162789 (UMLS CUI [1,1])
C0242957 (UMLS CUI [1,2])
C0242957 (UMLS CUI [1,2])
previous treatment
Item
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
boolean
C0087111 (UMLS CUI [1])
measureable disease
Item
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
boolean
C0475440 (UMLS CUI [1])
C0860888 (UMLS CUI [2])
C0860888 (UMLS CUI [2])
ecog performance status
Item
ecog performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
a life expectancy of > 3 months
boolean
C0023671 (UMLS CUI [1])
contraception
Item
use of effective means of contraception
boolean
C0700589 (UMLS CUI [1])
chemotherapy, herceptin
Item
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
boolean
C0392920 (UMLS CUI [1])
C0338204 (UMLS CUI [2])
C0338204 (UMLS CUI [2])